Immunotherapy drug improves survival for patients with head and neck cancer.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D007167:Immunotherapy; D000077594:Nivolumab
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000077594:Nivolumab